WO2001005366A1 - Composition de protection solaire sous forme d'aerosol - Google Patents

Composition de protection solaire sous forme d'aerosol Download PDF

Info

Publication number
WO2001005366A1
WO2001005366A1 PCT/US2000/019459 US0019459W WO0105366A1 WO 2001005366 A1 WO2001005366 A1 WO 2001005366A1 US 0019459 W US0019459 W US 0019459W WO 0105366 A1 WO0105366 A1 WO 0105366A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
mixtures
group
present
stabilizer
Prior art date
Application number
PCT/US2000/019459
Other languages
English (en)
Inventor
Thomas Russo
Joseph Hourihan
James Sanogueira
Original Assignee
Playtex Products, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Playtex Products, Inc. filed Critical Playtex Products, Inc.
Priority to MXPA02000457A priority Critical patent/MXPA02000457A/es
Priority to EP00947462A priority patent/EP1200054A1/fr
Priority to AU61065/00A priority patent/AU6106500A/en
Publication of WO2001005366A1 publication Critical patent/WO2001005366A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Definitions

  • the present invention relates to sunscreens. More particularly, the present invention relates to sunscreen compositions dispensed in the form of an aerosol product that foams.
  • Sunscreen compositions are applied to the skin to protect the skin from the sun's ultraviolet rays that can lead to erythema, a reddening of the skin also known as sunburn.
  • Sunlight or ultraviolet radiation in the UV-B range has a wavelength of 290nm to 320nm and is known to be the primary cause of sunburn.
  • Ultraviolet rays at a wavelength of 320nm to 400nm, known as UV-A radiation produces tanning of the skin. However, in the process of doing so, the UV-A rays can damage or harm the skin.
  • Another long-term effect is premature aging of the skin. This condition is characterized by skin that is wrinkled, cracked and has lost its elasticity.
  • sunscreens are typically formulated with the goal of inhibiting skin damage from the sun's rays.
  • the sunscreen composition filters or blocks the harmful UV-A and UV-B rays that can damage and harm the skin. It is believed that sunscreen agents accomplish this by absorbing the UV-A and/or UV-B rays.
  • sunscreen compositions are oil and water emulsions.
  • the UV-absorbing compounds are typically incorporated into the oil phase.
  • Sunscreens may also include physical or inorganic metal oxides that block the sun's rays. Titanium dioxide and zinc oxide are commonly used for this purpose.
  • SPF sun protection factor
  • a third consideration is product feel and how well the product spreads over the skin. Typically, consumers want a product that feels smooth and silky and be applied in a smooth continuous film over the skin. Another factor is the shelf life of the product, which is determined by the chemical and physical stability of the sunscreen composition.
  • product form will also play a part since there is a variety of choices such as lotions, gels, creams, sprays, and aerosols that are available. Form preference could ultimately determine whether the consumer decides to purchase the product.
  • the unique product forms can be appealing to many consumers who are looking for something different.
  • Sunscreens that are made in the form of an aerosol are not commonplace, particularly, aerosols that deliver the product as a foam.
  • the present invention in brief summary, is a sunscreen composition that is dispensed as an aerosol product.
  • the composition contains a sunscreen agent, an emulsifier, a foam builder/stabilizer, a counterion, and a propellant.
  • the sunscreen composition also contains an emollient, a humectant, a preservative/antioxidant, and water.
  • the ratio of the foam builder/stabilizer to counterion must be about 1 :4 to about 5:1.2. More preferably, the ratio is about 1 :1 to about 5:1.
  • the present invention is a sunscreen composition in the form of an aerosol comprising a sunscreen agent, an emulsifier, a foam builder/stabilizer, a counterion, and a propellant.
  • sunscreen agents that can be used in the present invention must be capable of absorbing or blocking the harmful effects of ultraviolet radiation. In addition, they must be non-toxic and non-irritating when applied to the skin. Suitable sunscreen agents include, for example, para- aminobenzoic acid (PABA), benzophenone-1 , benzophenone-2, benzophenone-3, benzophenone-4, benzophenone-6, benzophenone-8, benzophenone-12, methoxycinnamate, ethyl dihydroxypropyl-PABA, glyceryl PABA, homosalate, methyl anthranilate, octocrylene, octyl dimethyl PABA, octyl methoxycinnamate, octyl salicylate, PABA, 2- phenylbenzimidazole-5-sulphonic acid, triethanolamine salicylate, 3-(4- methylbenzylidene)-camphor, red petrolatum, and mixtures thereof.
  • PABA para-
  • the sunscreen agents may be present in an amount about 1 wt.% to about 40 wt.% of the total weight of the composition of the present invention.
  • the total amount of sunscreen agents in the composition will depend upon the sun protection factor (SPF) desired. Normally, the higher the SPF, the greater the total amount of sunscreen agents.
  • the sunscreen agents are included at about 4 wt.% to about 30 wt.%.
  • An emulsifier is an essential component of the present invention.
  • An emulsifier enables two or more immiscible liquids to be combined homogeneously, while increasing the viscosity of the composition.
  • Emulsifiers that may be used in the present invention include sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate, sorbitan trioleate, polyglyceryl-3- diisostearate, polyglycerol esters of oleic/isostearic acid, polyglyceryl-6 hexaricinolate, polyglyceryl-4-oleate, polygylceryl-4 oleate/PEG-8 propylene glycol cocoate, oleamide DEA, sodium glyceryl oleate phosphate, hydrogenated vegetable glycerides phosphate and mixtures thereof.
  • one or more synthetic polymers may be used as an emulsifier.
  • PVP Eicosene copolymer acrylat.es/C-io-C30 alkyl acrylate crosspolymer, acrylates/steareth-20 methacrylate copolymer, PEG-22/dodecyl glycol copolymer, PEG-45/dodecyl glycol copolymer, and mixtures thereof.
  • the preferred emulsifiers are PVP Eicosene copolymer, acrylates/C 10 -C 3 o alkyl acrylate crosspolymer, PEG-20 sorbitan isostearate, sorbitan isostearate, and mixtures thereof.
  • the one or more emulsifiers are present in a total amount about 0.01 wt.% to about 15 wt.% of the total weight of the composition of the present invention.
  • about 0.1 wt.% to about 3 wt.% of emulsifiers are used.
  • the composition of the present invention must include a foam builder/stabilizer.
  • the preferred foam builder/stabilizer is cetyl phosphate, DEA cetyl phosphate, TEA myristate, TEA stearate, magnesium stearate, sodium stearate, potassium laurate, potassium ricinoleate, sodium cocoate, sodium tallowate, potassium castorate, sodium oleate, and mixtures thereof.
  • the foam builder/stabilizer in an amount about 0.1 wt.% to about 5 wt.% must be added to the composition of the present invention.
  • the foam builder/stabilizer is present in an amount about 0.1 wt.% to about 3 wt.%.
  • Counterions are in the composition of the present invention to neutralize components such as an emulsifier and a foam builders/stabilizer.
  • Sodium hydroxide, potassium hydroxide, diethanolamine, triethanolamine, aminomethyl propanol, trisodium ethylenediaminetetraacetic acid, and mixtures thereof, are examples of suitable counterions used in the present invention.
  • the preferred counterion is triethanolamine.
  • Counterion is present in an amount about 0.01 wt.% to about 8 wt.% in the composition of the present invention. Preferably, counterion is present in an amount about 1 wt.% to about 5 wt.%.
  • a critical feature of the present invention is the ratio of the foam builder/stabilizer to counterion. To ensure superior foam quality and integrity, the ratio must be about 1 :4 to about 5:1.2. Preferably, the ratio is about 1 :1 to about 5:1.
  • Propellant The propellant must be capable of producing a sufficient pressure for expelling the composition from an aerosol container. Furthermore, the propellant must be non-irritating, non-toxic and compatible with the ingredients used in the composition. Suitable propellants are butane, isobutane, propane, dimethyl ether, dichlorodifluoromethane, tetrafluoromethane, dichlorotetrafluoroethane, chlorodifluoromethane, chlorodifluoroethane, difluoroethane, and mixtures thereof.
  • the preferred propellant of the present invention is a blend of isobutane and propane, commonly known as A-46 propellant.
  • Propellant is present in the range about 3 wt.% to about 15 wt.% of the present invention. Preferably, the propellant is about 5 wt.% to about 9 wt.%.
  • composition of the present invention optionally can have water.
  • Water can be present in an amount up to about 80 wt.%, preferably, from 30 wt.% to 70 wt.% of water.
  • the present composition may additionally contain one or more emollients.
  • An emollient provides a softening or soothing effect on the skin surface and is generally considered safe for topical use. Emollients also help control the rate of evaporation and the tackiness of the composition.
  • Preferred emollients include mineral oil, lanolin oil, coconut oil, cocoa butter, olive oil, aloe extracts, jojoba oils, castor oil, fatty acids such as oleic and stearic, fatty alcohols such as cetyl and hexadecyl (ENJAY), diisopropyl adipate, hydroxybenzoate esters, benzoic acid esters of C 9 -C-1 5 alcohols, isononyl iso-nonanoate, alkanes such as mineral oil, silicones such as dimethyl polysiloxane, ethers such as polyoxypropylene butyl ethers and polyoxypropylene cetyl ethers, and C ⁇ 2 -C 15 alkyl benzoates, and mixtures thereof.
  • the most preferred emollients are hydroxybenzoate esters, aloe vera, C ⁇ 2 -C 15 alkyl benzoates, and mixtures thereof.
  • Emollient is present in an amount about 1 wt.% to about 20 wt.% of the total weight of the composition.
  • the preferred amount of emollient is about 2 wt.% to about 15 wt.%, and most preferrably about 4 wt.% to about 10 wt.%.
  • Humectants A moistening agent, such as a humectant, may be incorporated into the present invention. Suitable humectants include glycerin, polyethylene glycol, polypropylene glycol, sorbitol, PEG-4, and mixtures thereof.
  • One or more humectants are optionally present at about 0.5 wt.% to about 8 wt.% in the present invention. Preferably, about 1 wt.% to about 5 wt.% of humectants may be used.
  • titanium dioxide may be added to the composition of the present invention.
  • This material is generally considered safe for topical use since it is physiologically inert and has a low degree of irritation and toxicity. It functions by reflecting and absorbing sunlight.
  • the titanium dioxide is suspended throughout the composition.
  • composition of the present invention may have about 0.5 wt.% to about 10 wt.% of titanium dioxide. Preferably, there is present about 1 wt.% to about 3 wt.% titanium dioxide.
  • preservatives/antioxidants may be in the present composition.
  • Diazolidinyl urea, iodopropynyl butylcarbamate, vitamin E, vitamin E acetate, vitamin C, butylated hydroxytoluene, methylparaben, and mixtures thereof may be a preservative/antioxidant in the present composition.
  • One or more preservatives/antioxidants may be present in an amount about 0.01 wt.% to about 2 wt.% of the total weight of the present invention. Preferably, one or more preservatives/antioxidants are present in an amount about 0.1 wt.% to about 1 wt.%.
  • the present invention may include a rheological additive, such as magnesium aluminum silicate, hydroxypropyl cellulose, carbomer, cellulose, guar gum, xanthan gum, bentonite, acrylate copolymers, and mixtures thereof.
  • a rheological additive such as magnesium aluminum silicate, hydroxypropyl cellulose, carbomer, cellulose, guar gum, xanthan gum, bentonite, acrylate copolymers, and mixtures thereof.
  • the rheological additive assists in building the viscosity of the present invention.
  • the rheological additive may optionally be present at about 0.05 wt.% to about 5 wt.% in the composition of the present invention.
  • rheological additives Preferably, about 0.1 wt.% to about 2 wt.% of rheological additives are present in the present composition.
  • the sunscreen composition of the present invention may also contain optional additives.
  • optional additives for instance, a fragrance, colorant, plant extract, absorbent, waterproofing agent, and mixtures thereof may be included.
  • the process used to manufacture the present invention must be capable of forming a homogeneous composition that can be sprayed or dispensed from an aerosol can.
  • aerosol products are made by filling a concentrate into a can and then filling the can with propellant under vacuum conditions.
  • the concentrate of the present invention may be prepared by using techniques and methods well known in the art. In general, ingredients are incorporated by mixing and applying heat if necessary, until the concentrate is uniform and homogeneous. If necessary, the concentrate may be homogenized to ensure homogeneity. The concentrate is then placed in an aerosol can which is later filled with propellant.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une composition de protection solaire sous forme d'un aérosol moussant. La composition contient un agent de protection solaire, un émulsifiant, un, un contre-ion, et un agent propulseur. Par ailleurs, le rapport adjuvant/stabilisateur de mousse d'une part, et contre-ion d'autre part est compris entre environ 1:4 et environ 5:1,2 afin de garantir une qualité et l'intégrité de la mousse.
PCT/US2000/019459 1999-07-15 2000-07-14 Composition de protection solaire sous forme d'aerosol WO2001005366A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MXPA02000457A MXPA02000457A (es) 1999-07-15 2000-07-14 Composicion protectora solar en aerosol,.
EP00947462A EP1200054A1 (fr) 1999-07-15 2000-07-14 Composition de protection solaire sous forme d'aerosol
AU61065/00A AU6106500A (en) 1999-07-15 2000-07-14 Sunscreen aerosol composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14426499P 1999-07-15 1999-07-15
US60/144,264 1999-07-15

Publications (1)

Publication Number Publication Date
WO2001005366A1 true WO2001005366A1 (fr) 2001-01-25

Family

ID=22507819

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/019459 WO2001005366A1 (fr) 1999-07-15 2000-07-14 Composition de protection solaire sous forme d'aerosol

Country Status (5)

Country Link
EP (1) EP1200054A1 (fr)
AU (1) AU6106500A (fr)
CA (1) CA2313955A1 (fr)
MX (1) MXPA02000457A (fr)
WO (1) WO2001005366A1 (fr)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011238A2 (fr) * 2001-07-31 2003-02-13 Merck Patent Gmbh Composition ecran solaire
KR20030013945A (ko) * 2001-08-10 2003-02-15 이인혜 분사형 선스크린제의 제조방법
WO2004071479A1 (fr) * 2003-02-12 2004-08-26 Connetics Australia Pty Ltd Mousse hydroalcoolique filmogene
WO2006099687A1 (fr) * 2005-03-24 2006-09-28 Ensign Laboratories Pty Ltd Spray aerosol solaire
WO2007002047A1 (fr) * 2005-06-20 2007-01-04 The Procter & Gamble Company Systeme de liberation de produit destine a atomiser des compositions cosmetiques pour la peau ou pour les cheveux contenant des filtres uv
US8173108B2 (en) 2009-11-04 2012-05-08 Conopco, Inc. Sunscreen composition
US8206691B2 (en) 2009-11-04 2012-06-26 Conopco, Inc. Sunscreen composition with fatty acid alkanolamides
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US8841778B2 (en) 1997-04-04 2014-09-23 Glenn J Leedy Three dimensional memory structure
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0791353A1 (fr) * 1996-02-26 1997-08-27 Shiseido Company Limited Composition absorbant les rayonnements ultraviolets

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0791353A1 (fr) * 1996-02-26 1997-08-27 Shiseido Company Limited Composition absorbant les rayonnements ultraviolets

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8907499B2 (en) 1997-04-04 2014-12-09 Glenn J Leedy Three dimensional structure memory
US8841778B2 (en) 1997-04-04 2014-09-23 Glenn J Leedy Three dimensional memory structure
WO2003011238A2 (fr) * 2001-07-31 2003-02-13 Merck Patent Gmbh Composition ecran solaire
WO2003011238A3 (fr) * 2001-07-31 2003-08-28 Merck Patent Gmbh Composition ecran solaire
KR20030013945A (ko) * 2001-08-10 2003-02-15 이인혜 분사형 선스크린제의 제조방법
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
WO2004071479A1 (fr) * 2003-02-12 2004-08-26 Connetics Australia Pty Ltd Mousse hydroalcoolique filmogene
US8562959B2 (en) 2003-02-12 2013-10-22 Stiefel Research Australia Pty Ltd Film foaming hydroalcoholic foam
US9211237B2 (en) 2003-02-12 2015-12-15 Stiefel Research Australia Pty Ltd Film foaming hydroalcoholic foam
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
WO2006099687A1 (fr) * 2005-03-24 2006-09-28 Ensign Laboratories Pty Ltd Spray aerosol solaire
WO2007002047A1 (fr) * 2005-06-20 2007-01-04 The Procter & Gamble Company Systeme de liberation de produit destine a atomiser des compositions cosmetiques pour la peau ou pour les cheveux contenant des filtres uv
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10946101B2 (en) 2009-10-02 2021-03-16 Vyne Therapeutics Inc. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US8206691B2 (en) 2009-11-04 2012-06-26 Conopco, Inc. Sunscreen composition with fatty acid alkanolamides
US8173108B2 (en) 2009-11-04 2012-05-08 Conopco, Inc. Sunscreen composition
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne

Also Published As

Publication number Publication date
MXPA02000457A (es) 2002-07-30
AU6106500A (en) 2001-02-05
CA2313955A1 (fr) 2001-01-15
EP1200054A1 (fr) 2002-05-02

Similar Documents

Publication Publication Date Title
WO2001005366A1 (fr) Composition de protection solaire sous forme d'aerosol
US6395269B1 (en) Sunscreen lotion or spray composition
US6190645B1 (en) Sunscreen for the scalp hair and hair
CA2461126C (fr) Compositions antisolaires
AU2003237369B8 (en) Sunscreen compositions
EP1594454B1 (fr) Mousse hydroalcoolique filmogene
EP1866033B1 (fr) Spray aerosol solaire
AU2002336539A1 (en) Sunscreen compositions
US6146618A (en) Disappearing color sunscreen compositions
CA2526626C (fr) Base d'emulsion pour compositions de soins de la peau
US5989529A (en) Substantive topical composition
JP3749548B2 (ja) 高ｓｐｆ日焼け止め処方物
US5208011A (en) Ultraviolet resistant sunscreen compositions
WO2002043490A1 (fr) Compositions insectifuges moussantes
AU671189B2 (en) Sunscreen compositions
JP2011506610A (ja) 酸化亜鉛存在下のリン酸塩ベースの乳化剤を用いるアボゼンゾンの光安定化増強
CN114630651B (zh) 具有低粘性的防晒组合物
MXPA02001664A (en) Sunscreen lotion or spray composition
AU2006227561B2 (en) Sunscreen aerosol spray
CN117320687A (zh) 包含贝莫三嗪醇的防晒组合物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/000457

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000947462

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000947462

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000947462

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP